Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Denies Priority Review For GlaxoSmithKline’s HPV Vaccine Cervarix

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision could give Merck’s Gardasil an extra four months without HPV vaccine competition.

You may also be interested in...



GSK Receives “Complete Response” Letter For Cervarix BLA

Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.

GSK Receives “Complete Response” Letter For Cervarix BLA

Drug maker will respond to FDA “as soon as possible” to answer outstanding questions related to the HPV vaccine.

GSK Rotarix Data Show Efficacy Against Virus Types Representing 98 Percent Of Rotavirus Disease

Data formed the basis of GSK’s BLA application for the rotavirus vaccine in the U.S., the company tells “The Pink Sheet” DAILY.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel